Experimental model of induction of diabetes mellitus in rats

Carvalho, Eliziane Nitz de; Carvalho, Nestor Antônio Schmidt de; Ferreira, Lydia Masako

doi:10.1590/s0102-86502003001100009

Cited by 61 publications

(68 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The rats were randomly divided into four equal groups of which three of the groups developed diabetes (type-1) by induction of the drug, alloxan (i.v.) at a dose of 30 mg/kg (Korec, 1980;Carvalho et al, 2003;Stetinova et al, 2007;Al-Salami et al, 2012). Two to three days after the administration of alloxan, rats that showed blood glucose levels of 418 mmol/L and showed the signs and symptoms of diabetes were considered diabetic (Alam & Rahman, 1971;Al-Salami et al, 2009).…”

Section: Diabetes Induction and In Vivo Analysismentioning

confidence: 99%

A comprehensive study of novel microcapsules incorporating gliclazide and a permeation enhancing bile acid: hypoglycemic effect in an animal model of Type-1 diabetes

et al. 2015

View full text Add to dashboard Cite

Context: Gliclazide (G) is a commonly prescribed drug for Type 2 diabetes (T2D). In a recent study, we found that when G was combined with a primary bile acid, and gavaged to an animal model of Type 1 diabetes (T1D), it exerted a hypoglycemic effect. We hypothesized this to be due to metabolic activation of the primary bile acid into a secondary or a tertiary bile acid, which enhanced G solubility and absorption. The tertiary bile acid, taurocholic acid (TCA), has shown strong permeation-enhancing effects in vivo. Thus, we aimed to design, characterize, and test microcapsules incorporating G and TCA in an animal model of T1D. Methods: Microcapsules were prepared using the polymer sodium alginate (SA). G-SA microcapsules (control) and G-TCA-SA microcapsules (test) were extensively examined (in-vitro) at different pH and temperatures. The microcapsules were gavaged to diabetic rats, and blood glucose and G concentrations in serum were examined. Ex-vivo studies were also performed using a muscle cell line (C2C12), and cell viability and glucose intake post-treatment were examined. Results: G-TCA-SA microcapsules showed good stability, uniformity, and thermal and chemical excipient compatibilities. TCA did not change the size or the shape of the microcapsules, but it enhanced their mechanical resistance and reduced their swelling properties. G-TCA-SA enhanced the viability of C2C12 cells over 24 hours, and exerted a hypoglycemic effect in alloxan-induced type-1 diabetic rats. Conclusions: The incorporation of TCA into G-microcapsules resulted in functionally improved microcapsules with a positive effect on cell viability and glycemic control in Type-1 diabetic animals.

show abstract

Section: Diabetes Induction and In Vivo Analysismentioning

confidence: 99%

A comprehensive study of novel microcapsules incorporating gliclazide and a permeation enhancing bile acid: hypoglycemic effect in an animal model of Type-1 diabetes

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Animals with blood glucose level > 200 mg/dl were considered diabetic and selected for the further experiment. Hyperglycemia maintenance was confirmed by the elevated fasting glucose levels in blood determined 15 days after injection 19 . Diabetic animals were kept with free access to food and water ad libitum for one month.…”

Section: Induction Of Diabetes and Diabetic Nephropathymentioning

confidence: 91%

Efficacy of Nateglinide and Pioglitazone Combination Therapy Compared With Monotherapy on Diabetic Nephropathy

Bigoniya¹,

Malvi²

2017

Int. J. Res. Ayurveda Pharm.

View full text Add to dashboard Cite

The objective of present work is to explore combined effect of nateglinide and pioglitazone on diabetic nephropathy. Nateglinide and pioglitazone were administered to the diabetic nephropathic animals as monotherapy and in median and high dose combination for 28 days. Body weight, relative kidney weight, serum and urine biochemical parameters were analyzed along with kidney tissue antioxidant level and histology. Loss in body weight was efficiently controlled by pioglitazone monotherapy and, nateglinide and pioglitazone high dose combination. Nateglinide treatment significantly (P < 0.05-0.001) reduced serum glucose, blood urea nitrogen (BUN), creatinine and insulin along with decrease in urine albumin and increase in creatinine. Both nateglinide and pioglitazone has significantly (P < 0.05-0.01) reduced glomerular filtration rate (GFR). Nateglinide has nonsignificant effect on kidney antioxidant level but pioglitazone has increased (P < 0.05) superoxide dismutase (SOD) level. Both median and high dose combination significantly (P < 0.05-0.001) reduced the elevated level of serum glucose, cholesterol, triglyceride, low density lipoprotein, BUN, creatinine, insulin and glycated haemoglobin. Combination doses were equally effective in decreasing albumin and increasing creatinine urinary excretion with increase in GFR. High dose combination significantly increased catalase, SOD and glutathione level in the kidney tissue. Monotherapy with nateglinide and pioglitazone reduce hyperglycemia and improve kidney functional ability. Both high and median dose combination of nateglinide and pioglitazone was found effective against disturbed serum and urine biochemical parameters. High dose combination was more effective and beneficial in ameliorating kidney pathological damage and oxidative stress in the treatment of diabetic nephropathy.

show abstract

“…The only animals that were included in the study were the ones that showed blood glucose levels above 200 mg/dL 26 . Animals belonging to the SCG and TCG received an equivalent dose of sodium citrate buffer solution, aiming to replicate the stress caused to diabetic groups.…”

Section: Induction Of Diabetes and Blood Glucose Controlmentioning

confidence: 99%

Resistance jump training may reverse the weakened biomechanical behavior of tendons of diabetic Wistar rats

Silva¹,

Castro²,

Coutinho³

et al. 2017

Fisioter. Pesqui.

View full text Add to dashboard Cite

Experimental model of induction of diabetes mellitus in rats

Cited by 61 publications

References 4 publications

A comprehensive study of novel microcapsules incorporating gliclazide and a permeation enhancing bile acid: hypoglycemic effect in an animal model of Type-1 diabetes

A comprehensive study of novel microcapsules incorporating gliclazide and a permeation enhancing bile acid: hypoglycemic effect in an animal model of Type-1 diabetes

Efficacy of Nateglinide and Pioglitazone Combination Therapy Compared With Monotherapy on Diabetic Nephropathy

Resistance jump training may reverse the weakened biomechanical behavior of tendons of diabetic Wistar rats

Contact Info

Product

Resources

About